Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Roche (OTCQX:RHHBY) received a CE mark for its Elecsys pTau217 blood test, developed with Eli Lilly, to detect Alzheimer’s-related amyloid pathology.
The single-assay test is intended to rule in or rule out amyloid pathology across primary and secondary care using a routine blood draw, with accuracy reported as comparable to cerebrospinal fluid diagnostics against PET-CT scans.
Roche (OTCQX: RHHBY) agreed to acquire PathAI to expand its digital pathology and AI diagnostics capabilities. Roche will pay USD 750 million upfront plus up to USD 300 million in milestone payments. Closing is subject to customary conditions, including antitrust and regulatory approvals, and is expected in the second half of 2026. The acquisition will fold PathAI into Roche Diagnostics and aims to scale PathAI’s AISight Image Management System globally, combine AI-driven pathology with Roche’s companion-diagnostics expertise, and accelerate biomarker discovery, translational research, and clinical trial support.
Roche (OTCQX: RHHBY) will present more than 45 abstracts at ARVO 2026 (3–7 May), including 20 oral presentations across five retinal conditions. Key disclosures include real-world VOYAGER data showing 6 months of Vabysmo retinal drying, Susvimo sustained-delivery findings, and early phase 2 vamikibart results.
Presentations cover nAMD, DME, RVO, UME and geographic atrophy with multiple posters and oral sessions scheduled in Denver.
Genentech (OTCQX: RHHBY) will present more than 45 abstracts, including 20 oral presentations, at ARVO 2026 (May 3-7) in Denver, covering five retinal conditions.
Key highlights include real-world 6-month Vabysmo retinal-drying data from VOYAGER, Susvimo data on sustained delivery, and early phase 2 vamikibart inflammation results.
Genentech (OTCQX: RHHBY) launched the All Eyes on DME public-awareness campaign on April 24, 2026, partnering with advocacy group diaTribe and comedian Damon Wayans to raise awareness of diabetic macular edema (DME).
The campaign highlights that 750,000 people in the U.S. live with DME, people of color face 2–3x higher risk, and about 60% of Americans with diabetes miss annual eye exams.
Roche (OTCQX: RHHBY) reported Group sales of CHF 14.7bn in Q1 2026: +6% at constant exchange rates, -5% in CHF and +9% in USD. Pharmaceuticals grew +7% CER (CHF 11.5bn) and Diagnostics +3% CER (CHF 3.3bn). Key clinical wins include positive phase III results for fenebrutinib (MS) and Gazyva (membranous nephropathy), CE mark for Elecsys NfL, launch of an NVIDIA AI factory, a definitive agreement to acquire SAGA Diagnostics, and a dividend increase to CHF 9.80. Outlook: mid single‑digit Group sales growth (CER) and high single‑digit core EPS growth (CER) for 2026.
Roche (OTCQX: RHHBY) reported that investigational fenebrutinib met primary endpoints in Phase III FENhance 1 and 2 in relapsing multiple sclerosis (RMS), cutting annualised relapse rates by 51.1% and 58.5% versus teriflunomide over 96 weeks.
Fenebrutinib also markedly reduced new T1-Gd+ and T2 brain lesions and showed positive trends on disability; total Phase III data will be submitted to regulators.
Genentech (OTCQX: RHHBY) reported positive Phase III FENhance 1 and 2 results for investigational fenebrutinib in relapsing multiple sclerosis (RMS). Fenebrutinib reduced annualized relapse rate by 51.1% and 58.5% versus teriflunomide over 96 weeks and cut new brain lesions markedly.
Secondary endpoints showed large MRI reductions and trends toward less confirmed disability progression; total RMS and PPMS data will be submitted to regulators.
Roche (OTCQX: RHHBY) reported Phase III METEOROID results showing ENSPRYNG (satralizumab) reduced risk of new MOGAD relapse by 68% versus placebo (p=0.0025), meeting the primary endpoint. At 48 weeks, 87% on ENSPRYNG were relapse-free vs 67% on placebo; onset observed by 8 weeks.
Key secondary results: ARR down 66% (p=0.0030); MRI active lesions down 79% (p=0.0026); rescue therapy use down 73% (p=0.0024). Safety aligned with established ENSPRYNG profile; no new safety signals. Data will be submitted to regulators globally.
Genentech (OTCQX: RHHBY) reported Phase III METEOROID results showing Enspryng (satralizumab) reduced risk of MOGAD relapse by 68% versus placebo (p=0.0025) and achieved 87% relapse-free at 48 weeks versus 67% for placebo. Key secondary endpoints (ARR, MRI lesions, rescue therapy) were also significantly improved. Data will be submitted to regulators globally; no new safety signals reported.